|
|
Volumn 14 Suppl 1, Issue , 1996, Pages
|
|
Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIBIOTIC;
DOXORUBICIN;
PROSTATE SPECIFIC ANTIGEN;
VINBLASTINE;
ARTICLE;
CELL CULTURE;
CELL DIVISION;
CELL SURVIVAL;
CYTOLOGY;
DISEASE COURSE;
DRUG EFFECT;
ENZYME IMMUNOASSAY;
HUMAN;
MALE;
METABOLISM;
NEOPLASM;
PATHOLOGY;
PROSTATE;
PROSTATE TUMOR;
SENSITIVITY AND SPECIFICITY;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CELL DIVISION;
CELL SURVIVAL;
DISEASE PROGRESSION;
DOXORUBICIN;
HUMANS;
IMMUNOENZYME TECHNIQUES;
MALE;
NEOPLASMS, HORMONE-DEPENDENT;
PROSTATE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
SENSITIVITY AND SPECIFICITY;
TUMOR CELLS, CULTURED;
VINBLASTINE;
MLCS;
MLOWN;
|
|
EID: 0029686392
PISSN: 07244983
EISSN: None
Source Type: Journal
DOI: 10.1007/bf00182061 Document Type: Article |
|
Times cited : (12)
|
|
References (0)
|
